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Abstract
Soy phosphatidylinositol (PI) containing lipid nanoparticles prolong plasma survival, improve 
hemostatic efficacy, and decrease immunogenicity of human B-domain deleted Factor VIII (BDD 
FVIII) in Hemophilia A (HA) mice. We hypothesize that PI associated BDD FVIII is more potent 
than the free protein, and using mathematical modeling, have projected that PI associated BDD 
FVIII could be used for once-weekly prophylactic dosing in patients. To facilitate translation to the 
clinic, comparative plasma survival and ex vivo efficacy of PI associated recombinant canine 
FVIII (PI-rcFVIII) were evaluated in HA dogs. 2 HA dogs were administered a 50 U/kg iv dose of 
free or PI-rcFVIII. rcFVIII activity measurements and ex vivo efficacy analyses like whole blood 
clotting time (WBCT) and thromboelastography (TEG) were conducted on recovered plasma and 
whole blood samples. PI association decreased clearance (~25%) and increased plasma exposure 
(~1.4 fold) of rcFVIII. PI-rcFVIII treated animals had prolonged improvements in WBCTs and 
TEG parameters compared to free rcFVIII treated animals. Since rcFVIII is a BDD form of FVIII, 
these studies provide proof-of-principle that observations with human BDD FVIII in mice 
translate to higher animal species. Additionally, PI-rcFVIII has potential applications in canine HA 
management and as a bypass therapy in inhibitor-positive HA patients.
INTRODUCTION
Hemophilia A (HA) is an X-linked bleeding disorder caused by the genetic deficiency or 
dysfunction of the essential blood coagulation protein Factor VIII (FVIII). Replacement 
therapy with recombinant human FVIII is currently the first line of therapy in HA 
management. However the short half-life (~12 hours1,2) and high incidence of immune 
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responses against the protein (nearly 30% of patients develop neutralizing antibodies3,4) 
have spurred the development of several next generation FVIII products 5-9.
A phosphatidylinositol (PI) containing lipidic nanoparticle for the delivery of B-domain 
deleted FVIII (BDD FVIII) has been developed10. These lipid nanoparticles extend the 
circulating half-life and hemostatic efficacy of BDD FVIII as well as mitigate immune 
responses against the protein, in a mouse model of HA. Lipidic BDD FVIII is more potent 
than the free form of the protein in HA mice10. The combined improvements in PK and PD 
have been predicted to substantially prolong the time above clinically established therapeutic 
thresholds, permitting once weekly prophylactic dosing of BDD FVIII.
The objective of this work was to evaluate whether the lipid-mediated improvements in the 
pharmacokinetics (PK) and pharmacodynamics (PD) of BDD FVIII observed in HA mice 
translate to higher species. For several decades, dogs with congenital HA have been used as 
a preclinical model to study the translational PK-PD of FVIII products11. These dogs 
replicate the genotypic and phenotypic characteristics of human HA with high fidelity, 12,13 
and this animal model has proved to be an excellent predictor of clinical efficacy14. HA dogs 
were therefore chosen as the animal model for these studies.
The canine FVIII protein has recently been recombinantly expressed and characterized15. 
Recombinant canine FVIII (rcFVIII) is a BDD form of FVIII and is secreted as a ~160kDa 
single chain protein15. rcFVIII was used as the model protein in these studies for two 
reasons. First, rcFVIII has important veterinary and clinical applications. It has been 
proposed as an attractive option for the management of canine HA and as a potential bypass 
strategy in human HA patients with inhibitors15. Second, the use of rcFVIII permits a 
prolonged evaluation of comparative PK-PD in these dogs in a crossover study design. Such 
evaluations are challenging with human FVIII forms because, despite high sequence 
homology between human and canine FVIII16, adult HA dogs develop antibodies against 
human FVIII, usually shortly after a single exposure15. Limited availability of animals and 
ethical considerations preclude the use of large sample sizes to study comparative efficacy of 
control and modified FVIII formulations in a parallel study design. Because rcFVIII is a 
BDD form of FVIII, studies in HA dogs with rcFVIII provide proof of principle that 
observations with human BDD FVIII in mice may translate to higher animal species.
Comparative PK and ex vivo PD studies with free and PI associated rcFVIII (PI-rcFVIII) 
were conducted in HA dogs. The results of these studies indicate that PI association does, in 
fact, improve the PK-PD properties of rcFVIII in HA dogs.
MATERIALS AND METHODS
Materials
rcFVIII was expressed, purified, and characterized as previously described15. The specific 
activity of the protein was 2.25 U/μg. Dimyristoylphosphatidylcholine (DMPC) and soybean 
PI were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol was 
purchased from Sigma-Aldrich (St.Louis, Missouri, USA). FVIII chromogenic assay 
detection kits were purchased from DiaPharma (Westchester, Ohio). Control plasmas and 
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activated partial thromboplastin time (aPTT) reagents were purchased from Precision 
Biologics (Dartmouth, Canada) and Tcoag (Parsippany, NJ) respectively. Buffer salts were 
purchased from Fisher Scientific.
Liposomal encapsulation and conformational studies
PI containing lipid nanoparticles (PI/DMPC/Cholesterol molar ratio 50:50:5) were prepared 
as previously described17. rcFVIII was associated with the PI nanoparticles using a 
‘triggered loading’ approach17. These loading conditions involve incubating the FVIII-lipid 
particle solution at 37°C for 30 min, which results in mild, reversible unfolding of the 
protein to promote interaction and loading18. The protein-to-lipid mole ratio for association 
was 1:20, 000 in all experiments unless stated otherwise. The activity of PI-rcFVIII was 
assessed by an aPTT assay prior to initiation of the study and was found to found to be 
comparable to that of free rcFVIII.
Encapsulation efficiency of rcFVIII with the PI particle was determined with discontinuous 
dextran gradient centrifugation19. Briefly, PI-rcFVIII was loaded into the bottom layer of a 
0%/10%/20% dextran gradient and subjected to ultracentrifugation at 190,000 X g for 30 
minutes. FVIII activity of each layer was measured after centrifugation in duplicate with the 
aPTT assay and compared to a standard curve of known rcFVIII activity. Encapsulation 
efficiency was determined by comparing FVIII activity in the upper layers to the lowest 
layer.
The tertiary structural changes in rcFVIII upon association with PI liposomes were assessed 
using fluorescence spectroscopy as previously described17. Free or PI-rcFVIII samples (5 
μg/mL) were excited at 265 or 280 nm and emission scans were collected in the wavelength 
range of 300-400 nm. Slit widths were set at 4 nm for both the excitation and emission 
paths. The spectra were acquired on a PTI-Quantamaster fluorescence spectrophotometer 
(Photon Technology International, Lawrenceville, New Jersey, USA). The contribution of PI 
vesicles on the emission spectra of the protein was corrected by subtracting the spectra 
acquired for the vesicles alone and by using a long pass filter on the emission path.
Animals
All animal work was conducted at the Francis Owen Blood Research Lab at the University 
of North Carolina (UNC), Chapel Hill, NC. The HA dogs used in these studies are an 
outbred model of severe hemophilia A due to an intron 22 inversion defect13. All 
experimental procedures were performed in accordance with the protocol approved by the 
Institutional Animal Care and Use Committee of UNC. The animals (n=2) used in these 
studies were female, inhibitor-negative and weighed~20kg each. Baseline characteristics of 
the animals used are presented in Table 1.
Preparation of free and PI-rcFVIII injections
PI lipid particles were prepared at the University at Buffalo and shipped to UNC overnight at 
2-8°C. rcFVIII was associated with lipid particles at UNC immediately prior to 
administration. It has previously been established that the duration and conditions of transit 
do not impact the stability or association efficiency of the PI particles. rcFVIII injections 
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were prepared by dilution into saline for the free protein, or into Tris-NaCl buffer (25mM 
Tris, 150mM NaCl, pH 7.0) for the lipid-associated protein.
Study Design
Studies were conducted in a crossover design. The 2 HA dogs had not received any FVIII 
for at least 2 weeks and were then first administered a single i.v. injection of free rcFVIII at 
a dose of 50 U/kg. Serial plasma and blood samples were collected from these animals at 
fixed time points post-injection (5min to 15d). After a ~3 week washout period, animals 
were administered a 50 U/kg i.v. PI-rcFVIII dose. Samples were collected at identical time 
points as after the free rcFVIII dose until whole blood clotting times (WBCT) values 
returned to baseline.
WBCT and thromboelastography (TEG) were performed using whole blood samples to 
evaluate ex vivo PD. WBCTs provide a rough measure of the activity of all intrinsic clotting 
factors in the absence of tissue factors. TEG provides information about the kinetics of clot 
formation using parameters such as R (reaction time; time of latency from the start of the 
test to initial clot formation), K (time taken to achieve a certain level of clot strength) is a 
measure of the rate of clot formation, Alpha measures the speed at which fibrin build up and 
crosslinking takes place (hence is also a measure of the rate of clot formation), and MA 
(maximum amplitude) represents the ultimate strength of the fibrin-cross linked clot. WBCT 
and TEG assessments were performed in real time, and plasma PK analyses were performed 
in batch after all the infusions and sample collections were completed. Plasma samples were 
stored at −80°C until analysis. Prior to administration of PI-rcFVIII at the end of the 
washout period, rcFVIII plasma concentrations were below the limit of quantification, and 
WBCTs and thromboelastography (TEG) parameters were confirmed (in real time) to have 
returned to baseline.
rcFVIII activity assays
Plasma rcFVIII activity levels were analyzed using both a one-stage aPTT assay optimized 
for this purpose20 and a commercially available two-stage chromogenic assay. Briefly, the 
aPTT assay was performed as follows: samples and standards of rcFVIII were diluted 1:10 
with imidazole buffered saline. The diluted plasma was then mixed 1:1 with FVIII deficient 
human plasma. A standard aPTT test was performed on 100 μl of this solution. For both 
assays, activities of free and PI-rcFVIII in plasma samples from the study animals were 
estimated from calibration curves constructed using a concentrate of corresponding form of 
the protein, spiked into pooled plasma from naïve HA dogs.
PK-PD modeling
Non-compartmental analysis (NCA) was performed on the resulting PK profiles in each 
individual dog using Phoenix WinNonlin v6.3 (Pharsight Corporation, Sunnyvale, CA) to 
compute basic PK parameters including: area under the curve (AUC), half-life (t1/2), 
clearance (CL), volume of distribution (Vss), and mean residence time (MRT). This was 
followed by compartmental modeling using various structural models to elucidate the 
disposition of free and PI-rcFVIII in HA dogs.
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PD modeling was performed on the WBCT and selected TEG (K) data. The final structural 
pharmacokinetic model and parameters (from modeling the chromogenic assay data) were 
fixed and used to drive the PD model. Several modifications of the Hill function were 
evaluated:
With E0 as the mean WBCT or K value in the absence of treatment, Emax is the maximum 
response, EC50 is the concentration of rcFVIII at which 50% response is observed, and the γ 
is the Hill coefficient. Model selection and evaluation of goodness of fit were guided by 
precision of the parameter estimates, objective measures like the Akaike information criteria, 
F-test and subjective measures like visual inspection of fitted profiles and residuals.
RESULTS
Encapsulation efficiency of rcFVIII with PI particle and conformation of PI-rcFVIII
The association efficiency of rcFVIII with PI nanoparticles was determined using 
discontinuous dextran gradient centrifugation. Fluorescence spectroscopy was used to 
evaluate tertiary structural changes in rcFVIII as a result of association with PI 
nanoparticles. Association of rcFVIII with PI particles was found to be less efficient than 
human BDD FVIII10, with 39.4 ± 3.2 % of recovered protein found in association with lipid 
particles. A blue shift in the fluorescence emission maximum of rcFVIII was observed in the 
presence of PI particles (Fig. 1), indicating a tertiary structural change attributable to 
hydrophobic interactions and deep penetration of the protein into the particle.
Pharmacokinetics
To investigate whether association with the PI particle prolongs plasma survival of rcFVIII, 
comparative PK studies were conducted at a dose of 50 U/kg IV. The PK profiles (Fig. 2) 
indicate that association of rcFVIII with the PI particle results in PK improvements. 
Whereas initial recoveries of plasma rcFVIII after free and PI-rcFVIII doses were 
comparable, the profiles diverged a few hours post-injection. FVIII activity in PI-rcFVIII 
treated animals was consistently greater than in animals treated with free rcFVIII. 
Meaningful FVIII activity levels (>0.01 U/mL) could be detected in animals treated with PI-
rcFVIII 8 hr (aPTT) to 16 hr (chromogenic assay) after FVIII activity became undetectable 
in animals treated with free rcFVIII.
Parameters calculated from non-compartmental analyses of PK profiles in each dog are 
summarized in Table 2. Volumes of distribution of both free and PI-rcFVIII were close to the 
physiological plasma volume in dogs (~50 mL/kg)21. Clearance of PI-rcFVIII was reduced 
by ~30% (chromogenic assay) to ~40% (aPTT) compared to free rcFVIII. Plasma exposure 
of PI-rcFVIII was ~ 1.4-fold (chromogenic assay) to ~1.7-fold (aPTT) greater compared 
with free rcFVIII. The terminal half-life of PI-rcFVIII was ~1.2 fold that of free rcFVIII in 
these HA dogs. A 1 compartment model with linear elimination was sufficient to describe 
the disposition of rcFVIII in these HA dogs. Final parameter estimates from the 
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compartmental model are shown in Table 3 and final model fitting to the data is shown in 
Fig. 2. As with NCA, clearance of PI-rcFVIII estimated by compartmental modeling was 
lower than free rcFVIII by ~25% (chromogenic assay) to ~35% (aPTT). An F-test was used 
to establish whether using treatment-specific clearance and volume of distribution estimates 
statistically improves model fitting compared to a model utilizing common estimates for 
both treatments (p<0.05). Additionally, confidence intervals around the clearance estimates 
of free and PI-rcFVIII do not overlap, suggesting statistical difference between the 
estimates.
Pharmacodynamics
Comparative ex vivo pharmacodynamics of free and PI-rcFVIII were evaluated using 
WBCT and TEG. The PD profiles obtained (Fig. 3-5) suggest that PI association prolongs 
the hemostatic efficacy of rcFVIII in HA dogs. Immediately post-injection, both free and PI-
rcFVIII corrected WBCTs to normal values (8-12 min). The return to a WBCT value of 20 
min (target level below which spontaneous bleeding is usually prevented in these HA dogs) 
was slower in one of the two dogs when treated with PI-rcFVIII (64 hr) as compared to free 
rcFVIII (48 hr). In addition, return of WBCT values to pre-treatment baseline levels was 
slower after PI-rcFVIII administration than after free rcFVIII administration. In both dogs, 
TEG parameters K, Alpha (data not shown) and MA showed clear improvements after 
treatment with PI-rcFVIII compared to free rcFVIII. It is interesting to note that MA values, 
which are a measure of the strength of the clot formed, were improved after PI-rcFVIII 
treatment compared to the free protein.
PK-PD modeling was conducted with the WBCT and TEG (K) data. Given the absence of a 
temporal lag between peak plasma concentrations and maximal effect (Fig 6), 
pharmacodynamic data were fit to a simple direct effect model. The use of this model to 
describe similar data in these HA dogs has previously been reported22. The final models that 
best described the efficacy data utilized a common EC50 value for free and PI-rcFVIII. The 
final model fit and estimated parameters are shown in Fig. 3 and 4 and Table 4. The 
available assays for FVIII plasma concentrations are not sensitive enough to follow the 
return of PD measures back to baseline values. The estimated EC50 values are therefore 
below the assay limits of quantification.
DISCUSSION
The development of a long acting, less immunogenic form of FVIII would fulfill a pressing 
clinical need. PI containing lipid nanoparticles can decrease the immunogenicity and 
prolong the plasma survival and hemostatic efficacy of human BDD FVIII in HA mice. 
Allometric predictions of comparative human PK suggest lipidic FVIII could be dosed once 
weekly for prophylactic purposes compared to thrice weekly with free FVIII, which would 
be a significant improvement in HA clinical management10. The objective of this work was 
to evaluate whether the lipid-mediated improvements in BDD FVIII PK and PD observed in 
HA mice translate to higher preclinical species. PK and PD studies with free and PI 
associated rcFVIII were conducted in HA dogs, which have long been recognized as an 
excellent preclinical model of the disease. Because the recently expressed rcFVIII protein is 
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a BDD form of FVIII with important veterinary and clinical applications, this protein was 
used to establish proof of principle.
A smaller percentage of rcFVIII compared to human BDD FVIII associated with PI 
nanoparticles even at double the protein-to-lipid mole ratio. Although the cause for this has 
not been investigated in detail, a possible reason is that the lipid binding domain of rcFVIII 
might be inaccessible for interactions with the lipid particles under the ‘triggered loading’ 
conditions we use for association17. Alternatively, the single chain structure of rcFVIII, as 
opposed to the double chain structure of human BDD FVIII, could result in altered dynamics 
of the protein-lipid particle interaction. However, a blue shift in the fluorescence emission 
maximum of rcFVIII upon PI association suggested that the fraction of the protein that is 
associated with the particle is likely deeply embedded within the lipid bilayer. This could 
result in meaningful protection against catabolism of this fraction in vivo.
Plasma PK profiles following i.v. bolus doses of both free and PI-rcFVIII were characterized 
by a mono-exponential decrease in plasma FVIII activity. Non-compartmental and 
compartmental analyses indicated that PI association decreases the clearance and prolongs 
plasma survival of BDD FVIII. The mechanisms underlying this decrease in clearance have 
not yet been investigated. However, we postulate that they are similar to those reported for 
human BDD FVIII (i.e. PI association sterically shields rcFVIII from receptor mediated 
clearance and proteolytic degradation10). The fact that the prolongation in terminal half-life 
is not as pronounced as that observed with human BDD FVIII in HA mice10 is likely due to 
the lower association efficiency of rcFVIII with the PI-particle. Experimental modifications 
to increase this association efficiency could lead to further improvement in the plasma 
survival of rcFVIII in these dogs. As is, PI association prolongs the time before plasma 
rcFVIII activity decreases to the threshold of 0.02 U/mL by ~12 hours (Fig. 2a). This 
threshold represents the free rcFVIII plasma concentration required to maintain WBCT of 
20 min (Fig. 6a).
Ex vivo PD data indicate that lipid association prolongs hemostatic efficacy of rcFVIII in 
HA dogs. Both WBCTs and TEG parameters showed prolonged improvements post PI-
rcFVIII administration. This prolongation is attributable to the fact that PI association 
prolongs plasma survival of rcFVIII (Fig. 6). The time before plasma concentrations 
decrease to a minimum therapeutic threshold is therefore longer for PI-rcFVIII than for the 
free protein. Unlike with human FVIII, there was no improvement in potency of rcFVIII 
upon PI association. In the case of both free and PI-rcFVIII, average WBCT values of 20 
min require mean plasma rcFVIII activity levels of ~0.02 U/mL. If PI-rcFVIII was more 
potent than the free form of the protein, a lower concentration of the lipidic protein would 
have sufficed to maintain WBCTs of 20min. This is corroborated by the fact that modeling 
the WBCT and K data using treatment-specific EC50 parameters results in similar estimates 
of EC50 values for both treatments. We hypothesize that the improved activity of PI 
associated FVIII could be due to stabilization of the activated FVIII hetero-trimer upon 
association with the lipid particle10. However, it has been shown that the activated form of 
rcFVIII is much more stable than activated human FVIII15. It is therefore possible that the 
stabilizing effects of PI association on the activated hetero-trimer are not as evident with 
rcFVIII as they are with human FVIII. In addition, the efficacy studies reported here were 
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conducted ex vivo. The difference in potency might become apparent in an in vivo setting, in 
the presence of physiologically relevant, global hemostasis machinery. Such evaluations will 
be the subject of future work. An important caveat to these interpretations remains that 
nearly 60% of the protein administered in the PI-rcFVIII treatment was unassociated with 
the lipid particle.
Regardless of the underlying mechanisms, these studies provide proof of principle that the 
lipid-mediated prolongation in BDD FVIII plasma survival we have observed in HA mice 
translates to HA dogs and results in prolonged hemostatic efficacy which is the clinically 
meaningful endpoint. The translation of the enhanced potency we have observed with human 
BDD FVIII in HA mice to HA dogs, would further improve this prolongation in efficacy. 
Such evaluations with human BDD FVIII in HA dogs will be the subject of future work.
CONCLUSIONS
In summary, the association of rcFVIII with PI-containing lipidic nanoparticles prolongs 
plasma survival and hemostatic efficacy of this protein in HA dogs. These findings serve as 
proof-of-principle that the lipid-mediated improvements in the PK properties of human BDD 
FVIII observed in HA mice translate to higher species. Lipid-associated rcFVIII also has 
direct applications in the veterinary management of canine HA. PI association protects 
human BDD FVIII from inactivation by inhibitors in HA mice (unpublished results). Similar 
protection of rcFVIII would enhance the efficacy of this protein as a bypass therapy in 
inhibitor-positive subjects and future studies could explore this possibility. Lipidic FVIII 
therefore is a promising approach to improve quality of care in both human and canine 
Hemophilia A.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institutes of Health to Dr. Balu-Iyer (R01 HL-70227) and Dr. 
Nichols (HL-63098). The authors thank Pharmaceutical Sciences Instrumentation facility, University at Buffalo, 
State University of New York, for use of the shared microplate reader, ultracentrifuge and fluorescence 
spectrometer.
ABBREVIATIONS USED
FVIII Factor VIII
BDD FVIII B-domain deleted Factor VIII
rcFVIII recombinant canine Factor FVIII
HA Hemophilia A
PK pharmacokinetic
PD pharmacodynamic
PI phosphatidylinositol
DMPC dimyristoylphosphatidylcholine
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aPTT activated partial thromboplastin time
WBCT whole blood clotting time
TEG thromboelastography
NCA non-compartmental analysis
AUC area under the curve
t1/2 half-life
CL clearance
Vss volume of distribution
MRT mean residence time
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Figure 1. Normalized florescence emission spectra of free and PI-rcFVIII
Normalized fluorescence emission spectra of free rcFVIII (solid line) and PI-rcFVIII 
(dashed line) acquired in the range of 300–400 nm. The excitation monochromator was set 
at 280 nm. The protein concentration used was 5 μg/mL.
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Figure 2. Pharmacokinetics of free and PI-rcFVIII
PK profiles of free and PI-rcFVIII in HA dogs after an i.v. bolus dose of 50 U/kg. FVIII 
activity in recovered plasma samples was measured using the two-stage chromogenic (2a) 
and one-stage aPTT assays (2b). The solid and dashed lines represent the fit of a 1 
compartment model with linear elimination to free and PI-rcFVIII data respectively. PI 
association prolongs plasma survival of rcFVIII. PI-rcFVIII has lower CL, consistent with 
the hypothesis of protection against uptake by clearance receptors and proteolytic 
degradation. * No FVIII activity was detected in the 72hr (chromogenic assay) and 48 hr 
(aPTT) samples from free rcFVIII treated animals.
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Figure 3. WBCT data and model fit
WBCT vs time profiles after i.v. bolus doses of 50 U/kg free and PI-rcFVIII in HA dogs. 
Circles represent individual observed values and the lines represent the model fit. The 
dashed blue line represents a WBCT of 20 min-the threshold below which spontaneous 
bleeding is prevented in these dogs. Dotted blue lines represent the WBCT range in dogs 
with a normal clotting phenotype (8-12 min). Dotted black and red lines represent mean 
baseline WBCT values prior to free and PI-rcFVIII administration respectively. rcFVIII 
treatment corrected clotting phenotype to normal levels immediately post dose followed by 
return to baseline over time which was more gradual after PI-rcFVIII treatment. Return to 
WBCT values of 20min was prolonged after PI-rcFVIII treatment in one dog.
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Figure 4. TEG (K) data and model fit
TEG (K) values over time after i.v. bolus doses of 50 U/kg free and PI-rcFVIII in HA dogs. 
The parameter K provides an estimate of the rate of clot formation. Circles represent 
individual observed values and the lines represent the model fit. rcFVIII treatment corrected 
clotting phenotype to normal levels immediately post dose followed by return to baseline 
over time which was more gradual after PI-rcFVIII treatment.
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Figure 5. Comparative MA of free and PI-rcFVIII
TEG (MA) values over time after i.v. bolus doses of 50 U/kg free and PI-rcFVIII in HA 
dogs. The parameter MA provides an estimate of the strength of the clot formed. Circles 
represent individual observed values and the lines represent mean MA over time. The 
strength of the clot formed in whole blood samples was higher after treatment with PI-
rcFVIII compared with the free protein.
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Figure 6. PK-PD overlays
Overlay of PK and PD profiles after free (6a) and PI-rcFVIII (6b) treatment. WBCT of 20 
min requires ~0.02U/mL of both free and PI-rcFVIII. However, time to decline to mean 
WBCT of 20 min is prolonged with PI-rcFVIII.
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Table 1
Baseline characteristics of study dogs
Animal ID Sex Weight (kg) FVIII:C (U/mL)a WBCT (min)
TEG
R(min) K(min) Angle(°) MA(mm)
Daisy F 19.7 <0.006 41 >60
na
b na na
Nora F 19.4 <0.006 39.5 58.9 45.5 4 24.4
a
Determined using a two-stage chromogenic assay
bNot available
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Table 2
Non-compartmental analyses parameter estimates
Parameter
Chromogenic assay aPTT
Free rcFVIII PI-rcFVIII Free rcFVIII PI-rcFVIII
Cmax (U/mL) 1.82, 1.52 1.61, 1.55 1.76, 1.12 2.03, 1.69
AUC0–τ (h × U/mL) 10.8, 16.1 16.0, 22.2 7.44, 11.4 12.5, 19.7
CL (mL/h × kg) 4.58, 3.03 3.08, 2.23 6.59, 4.18 3.95, 2.52
Vss (mL/kg) 47.7, 38.7 36.8, 36.9 41.3, 47.3 33.6, 28.3
MRT (hr) 9.99, 11.4 11.1, 15.8 5.61, 9.56 7.89, 11.0
T1/2 (hr) 8.28, 9.93 9.26, 11.6 5.31, 8.18 7.32, 7.34
Cmax = maximum plasma concentration, AUC0–τ = area under the concentration-time curve, CL = clearance, Vss= volume of distribution, 
MRT= mean residence time, T1/2= half-life
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Table 3
Pharmacokinetic model parameter estimates
Parameter
Chromogenic assay aPTT
Free rcFVIII PI-rcFVIII Free rcFVIII PI-rcFVIII
CL (CV%) (mL/h × kg) 3.16(5.33) 2.44(5.39) 4.49(8.74) 2.97(8.37)
Vss (CV%) (mL/kg) 40.2(6.05) 40.6(11.1) 30.6(10.6)
CL = clearance, Vss= volume of distribution
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Table 4
Pharmacodynamic parameter estimates
Parameter WBCT K
E0(CV%) (min) 51.5 (2.48) 27.2 (3.94)
Emax(CV%) 0.8 (3.23) 0.97 (1.18)
EC50(CV%) (U/mL) 0.002 (27.4) 0.0002 (27.0)
γ(CV%) 0.6 (17.5) 0.5 (12.4)
E0= mean WBCT or K value in the absence of treatment, Emax = maximum response, EC50 = concentration of rcFVIII at which 50% response is 
observed, γ= Hill coefficient
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